Despite Effectiveness, Accelerated Approval For Acute Hepatic Porphyria Drug in Doubt
Arcaion / Pixabay

Despite Effectiveness, Accelerated Approval For Acute Hepatic Porphyria Drug in Doubt

According to a story from wtvbam.com, the drug development company Alnylam Pharmaceuticals has recently stated that it is looking less likely that its gene silencing therapy givosiran will be getting…

Continue Reading Despite Effectiveness, Accelerated Approval For Acute Hepatic Porphyria Drug in Doubt